๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.

RecruitingNAAges 45 Years - 74 YearsFemaleMoscow Clinical Scientific Center
NCT04800393 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Even decade ago it was believed that the choice method of anesthesia did not affect the course of the oncological process, but recent evidence has begun to emerge that inhalation anesthesia vs TIVA is associated with a higher number of adverse outcomes. Apparently, it makes sense to conduct mRCT in order to assess the effect of IA on immune system in patients operated on for breast cancer comprehensively. The results of that kind of RCT may finally give us an answer whether the choice of anesthesia affects the immune status of patients undergoing surgery for breast cancer. The evaluation of complications and long-term survival will allow to recommend to use or not to use IA for this type of surgery. Objective: The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * The age of the patients is from 45 to 74 years; * Primary operable breast cancer (BC) without prior chemotherapy; * Cytologically confirmed breast malignant tumor of IA-IIA stages (T1-2, N0, M0); * Signed informed consent. Exclusion Criteria: * Acute cerebrovascular accident (CVA) occurred in the previous 6 months; * Myocardial infarction (MI) occurred in the previous 6 months; * Acute arterial thrombosis occurred in the previous 6 months; * Acute venous thromboembolism occurred in the previous 6 months; * Subarachnoid hemorrhage occurred during the previous 3 months; * Chronic kidney disease (CKD) stage 3B-5; * ะกhronic heart failure (NYHA) class 3-4; * Pregnancy; * History of another location cancer; * History of drug addiction; * Autoimmune diseases in history; * Post-randomization: withdrawal of informed consent (refusal to continue participating in the study); * Post-randomization: surgical intervention, performed not in full (verified non-resected lesions in the early p/o period, 2 weeks p/o).
๐Ÿ’Š

What it tests

  • Sevoflurane
  • Propofol
๐Ÿ“

Where

1 site
Moscow Scientific Clinical Center
Moscow, Russia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy